160 billion won Daewoong·Takeda Luphere·Leuplin

20 to 30 billion performance banding competition.

Daewoong Pharmaceutical's Luphere and Takeda Pharmaceutical Leuplin are leading the market in the field of prostate cancer treatment.

 

According to the drug distribution performance data, Luphere and Leuplin ranked 1st and 2nd based on single product sales in the first half of this year, with a performance of 15.4 billion won and 13.9 billion won, respectively.

 

In the last five years, these two products have been fiercely competing for a leading position.

 

In 2019-2020, Leuplin surpassed Luphere, which recorded 21.5 billion and 22.4 billion won at 32.2 billion and 315 billion won, and in 2021 and 2022, Luphere surpassed Leuplin, which achieved 242 billion and 27.5 billion won with 30.7 billion and 30.4 billion won.

 

Ipsen Korea's Diphereline, which ranked third, recorded 22.7 billion, 24.8 billion won, and 13.7 billion won in 2021 and 2022.

 

The noteworthy point is that in the first half of 2023, the combined performance of Digital herelin PR/SR is 162 billion won, which is more than the performance of Luphere and Leuplin.

 

Diphereline is growing from 200 million in 2019 to 4.5 billion won in 2022, and Diperellin pier is also expanding its appearance from 8.9 billion in 2019 to 248 billion won in 2022.

 

In the first half of this year, Hanol Eligard, AZ Zoladex Depo, Zoladex LA depo, and Lorelin Depo recorded sales of about '9.5 billion', '8.8 billion won, and '7 billion' respectively.

 

In the past three years, the combined sales of Zoladex Depot and Zoladex LA depot have been at the top with 26.4 billion won, 30.7 billion won, and 331 billion won.

 

Ferring Pharmaceutical Permagon, which remains at the bottom of the ranking, showed a slight increase in sales compared to last year, with a performance of 130 million won in the first half of this year.

 

The reason for the low sales is identified as the acquisition of a single indication compared to competing products.

 

Indications for Luphere and leuplin, include prostate cancer, endometriosis, premenopausal breast cancer, central puberty, and reduction of myoma.

 

Zoladex has the most various efficacy effects, such as prostate cancer, endometriosis, premenopausal breast cancer, and assisted reproduction for pituitary inhibition and adjuvant therapy for early breast cancer in the process of ovulation.

 

7.5 mg and 22.5 mg of leuprorelinacetate is used to relieve advanced prostate cancer, and 45 mg is used for central puberty.

 

The market for prostate cancer and precociousness treatments has grown from 118.9 billion won in 2019 to 1607 billion won in 2022, an increase of 35% over three years.